Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel for patients with R/R indolent non-Hodgk...

Full description

Bibliographic Details

Published in:	Blood Vol. 143; no. 6; p. 496
Main Authors:	Neelapu, Sattva S, Chavez, Julio C, Sehgal, Alison R, Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Oluwole, Olalekan O, Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A Scott, Miao, Harry, Beygi, Sara, Jacobson, Caron A
Format:	Journal Article
Language:	English
Published:	United States 08.02.2024
Subjects:	Antigens, CD19 - therapeutic use Biological Products - therapeutic use Follow-Up Studies Humans Immunotherapy, Adoptive - adverse effects Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, Follicular - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Neoplasm Recurrence, Local - drug therapy
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!